Processa Pharmaceuticals (PCSA) Stock Forecast, Price Target & Predictions
PCSA Stock Forecast
Processa Pharmaceuticals stock forecast is as follows: an average price target of $9.00 (represents a 571.64% upside from PCSA’s last price of $1.34) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
PCSA Price Target
The average price target for Processa Pharmaceuticals (PCSA) is $9.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $9.00. This represents a potential 571.64% upside from PCSA's last price of $1.34.
PCSA Analyst Ratings
According to 2 Wall Street analysts, Processa Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for PCSA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Processa Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 19, 2022 | - | Maxim Group | $9.00 | $3.18 | 182.62% | 571.64% |
The latest Processa Pharmaceuticals stock forecast, released on Apr 19, 2022 by Maxim Group company, set a price target of $9.00, which represents a 182.62% increase from the stock price at the time of the forecast ($3.18), and a 571.64% increase from PCSA last price ($1.34).
Processa Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.34 | $1.34 | $1.34 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Processa Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Processa Pharmaceuticals's last price of $1.34. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 12, 2023 | Maxim Group | Buy | Buy | Hold |
| Aug 03, 2021 | Oppenheimer | - | Outperform | Initialise |
Processa Pharmaceuticals's last stock rating was published by Maxim Group on Jan 12, 2023. The company gave PCSA a "Buy" rating, the same as its previous rate.
Processa Pharmaceuticals Financial Forecast
Processa Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Processa Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PCSA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Processa Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict PCSA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Processa Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Processa Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-1.43M | $-1.40M | $-1.64M | $-1.97M | $-2.27M | $-2.98M | $-3.01M |
| High Forecast | $-1.43M | $-1.40M | $-1.64M | $-1.97M | $-2.27M | $-2.98M | $-3.01M |
| Low Forecast | $-1.43M | $-1.40M | $-1.64M | $-1.97M | $-2.27M | $-2.98M | $-3.01M |
| Surprise % | - | - | - | - | - | - | - |
Processa Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PCSA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Processa Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Processa Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PCSA last annual SG&A of $NaN (undefined).
Processa Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.48 | $-0.47 | $-0.55 | $-0.66 | $-0.76 | $-1.00 | $-1.01 |
| High Forecast | $-0.48 | $-0.47 | $-0.55 | $-0.66 | $-0.76 | $-1.00 | $-1.01 |
| Low Forecast | $-0.48 | $-0.47 | $-0.55 | $-0.66 | $-0.76 | $-1.00 | $-1.01 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Processa Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PCSA previous annual EPS of $NaN (undefined).
Processa Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKTX | Akari Therapeutics | $3.26 | $12.00K | 367998.16% | - |
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| PCSA | Processa Pharmaceuticals | $1.34 | $9.00 | 571.64% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| FENC | Fennec Pharmaceuticals | $5.47 | $15.75 | 187.93% | Buy |
| CELC | Celcuity | $14.98 | $31.50 | 110.28% | Buy |
| SABS | SAB Biotherapeutics | $2.79 | $5.67 | 103.23% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| ELVN | Enliven Therapeutics | $22.32 | $33.00 | 47.85% | Buy |
| THRD | Third Harmonic Bio | $13.57 | $16.15 | 19.01% | Buy |
PCSA Forecast FAQ
Is Processa Pharmaceuticals a good buy?
Yes, according to 2 Wall Street analysts, Processa Pharmaceuticals (PCSA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of PCSA's total ratings.
What is PCSA's price target?
Processa Pharmaceuticals (PCSA) average price target is $9 with a range of $9 to $9, implying a 571.64% from its last price of $1.34. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Processa Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for PCSA stock, the company can go up by 571.64% (from the last price of $1.34 to the average price target of $9), up by 571.64% based on the highest stock price target, and up by 571.64% based on the lowest stock price target.
Can Processa Pharmaceuticals stock reach $2?
PCSA's average twelve months analyst stock price target of $9 supports the claim that Processa Pharmaceuticals can reach $2 in the near future.
What are Processa Pharmaceuticals's analysts' financial forecasts?
Processa Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-8.264M (high $-8.264M, low $-8.264M), average SG&A $0 (high $0, low $0), and average EPS is $-2.77 (high $-2.77, low $-2.77). PCSA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-6.444M (high $-6.444M, low $-6.444M), average SG&A $0 (high $0, low $0), and average EPS is $-2.16 (high $-2.16, low $-2.16).